STRYKER Business Summary

Stryker Corporation (SYK) operates a diversified medical technology business model, generating $25.1 billion in 2025 revenue through the sale of surgical equipment, orthopedic implants, neurotechnology devices, and recurring service contracts. The company is organized into two primary reporting segments: MedSurg and Neurotechnology, which contributed approximately $15.6 billion in 2025 sales across endoscopy, instruments, and neurovascular products; and Orthopaedics, which generated $9.5 billion through joint replacement and trauma solutions. Stryker utilizes an integrated ecosystem strategy, leveraging its Mako SmartRobotics platform to drive high-margin disposable sales and long-term hospital capital lock-in. Its primary direct competitors include Medtronic, Johnson & Johnson (DePuy Synthes), Zimmer Biomet, and Smith & Nephew, with Stryker maintaining a dominant market position specifically in robotic-assisted surgery and extremities following its strategic acquisition of Wright Medical. Founded in 1941 by orthopedic surgeon Dr. Homer Stryker, the company is currently led by Chair and CEO Kevin Lobo, who has overseen a period of aggressive M&A and organic growth since 2012. The executive team was recently bolstered by the appointment of Spencer Stiles as President and Chief Operating Officer (effective January 1, 2026), a 27-year veteran of the firm, and Preston Wells as Vice President and Chief Financial Officer. Technical and digital strategy is directed by Debra King, Vice President and Chief Digital and Information Officer, while Dr. Mark Rachlin leads Global Research & Development. The Board of Directors features notable figures including Ronda Stryker, a billionaire philanthropist and granddaughter of the founder, and Lead Independent Director Sherilyn McCoy, former CEO of Avon Products and a long-time executive at Johnson & Johnson.